MedTrace Logo

Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer

NCT07214142 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-10-09

No results posted yet for this study

Summary

Research Objective:To investigate the efficacy and safety of the "total neoadjuvant chemoradiotherapy combined with immunotherapy" regimen for the treatment of locally advanced rectal cancer with high-risk features for recurrence.

Study Design:A single-arm, multicenter clinical study.

Study Population: Patients with locally advanced rectal cancer presenting with high-risk features for local recurrence.

Conditions

  • Rectal Cancer Patients

Interventions

DRUG

PD-1

patients will receive short-course chemotherapy and concurrent PD-1

Sponsors & Collaborators

  • The First Affiliated Hospital of University of Science and Technology of China

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2027-12-31
Completion
2030-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07214142 on ClinicalTrials.gov